Results of a Phase II Study to Determine the Efficacy and Safety of Genetically Engineered Allogeneic Human Chondrocytes Expressing TGF-β1

Abstract

Genetically engineered chondrocytes virally transduced with a transforming growth factor (TGF)-β1 (TG-C [TissueGene-C]) expression vector have been shown to have potential benefits in the nonoperative management of knee osteoarthritis. Previous literature has reported on safe dosages of TG-C. Therefore, the purpose of this study was to evaluate the Phase II results and a 24-month efficacy of this injectable mixture compared with placebo in patients with Kellgren–Lawrence (K–L) grade III knee osteoarthritis. Specifically, we assessed (1) functional outcomes, (2) pain scores, (3) adverse events (AEs), and (4) magnetic resonance imaging (MRIs) findings. We performed a multicenter, double-blinded, placebo-controlled, and randomized study of adults who had K–L grade III knee osteoarthritis. A total of 102 patients were 2:1 randomized to TG-C at a dose of 3.0 × 10⁷ cells, or placebo injections between May 1, 2011 and October 31, 2012. Outcomes analyzed were knee joint function, pain, quality of life, adverse events, and MRI findings using the whole-organ magnetic resonance imaging score (WORMS) system. There were significant improvements in the International Knee Documentation Committee (IKDC) and visual analogue scale (VAS) scores in the TG-C cohort, when compared with the placebo cohort at weeks 12, 52, 72, and 104 (p < 0.05). No severe AEs were observed. Common AEs were arthralgia, joint inflammation, and joint effusion which were similar between both cohorts. Whole-knee MRIs at 12 months showed less progression of cartilage damage, infrapatellar fat pad-synovitis, and effusion-synovitis in the TG-C cohort. Patients who received TG-C had significant improvements in IKDC and VAS scores. These patients also reported less severe and frequent pain. Additionally, fewer patients treated with TG-C showed progression of cartilage damage, as well as less progression of infrapatellar fat pad synovitis and effusion-synovitis. Furthermore, treatment with TG-C was generally well tolerated with minor AEs. Therefore, based on these results, TG-C appears to be a safe and effective modality for the management of K–L grade III osteoarthritis.

Keywords

genetically modified - growth factors - knee - osteoarthritis - pain

• References

• 1 Cetin N, Aytar A, Atalay A, Akman MN. Comparing hot pack, short-wave diathermy, ultrasound, and TENS on isokinetic strength, pain, and functional status of women with osteoarthritic knees: a single-blind, randomized, controlled trial. Am J Phys Med Rehabil 2008; 87 (06) 443-451
• 2 Johnson AJ, Starr R, Kapadia BH, Bhave A, Mont MA. Gait and clinical improvements with a novel knee brace for knee OA. J Knee Surg 2013; 26 (03) 173-178
• 3 Ruiz Jr D, Koenig L, Dall TM. , et al. The direct and indirect costs to society of treatment for end-stage knee osteoarthritis. J Bone Joint Surg Am 2013; 95 (16) 1473-1480
• 4 Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am 2014; 96 (08) 624-630
• 5 Dagenais S, Kang A, Scranton R. A comparison of total hospitals costs for medicare patients undergoing total knee arthroplasty with or without bupivacaine liposomal injectable suspension. Value Health 2016; 19 (03) A230
• 6 Liu T-ST, Weiss KR, Fu FH, Huard J. Gene therapy and tissue engineering in orthopaedic surgery. Instr Course Lect 2006; 55: 597-611
• 7 Balakrishnan B, Joshi N, Jayakrishnan A, Banerjee R. Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration. Acta Biomater 2014; 10 (08) 3650-3663
• 8 Somoza RA, Welter JF, Correa D, Caplan AI. Chondrogenic differentiation of mesenchymal stem cells: challenges and unfulfilled expectations. Tissue Eng Part B Rev 2014; 20 (06) 596-608
• 9 Cavallo C, Filardo G, Mariani E. , et al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am 2014; 96 (05) 423-429
• 10 Richardson SM, Kalamegam G, Pushparaj PN. , et al. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods 2016; 99: 69-80
• 11 Piuzzi NS, Khlopas A, Newman JM. , et al. Bone marrow cellular therapies: novel therapy for knee osteoarthritis. J Knee Surg 2018; 31 (01) 22-26
• 12 Chahla J, Cinque ME, Piuzzi NS. , et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am 2017; 99 (20) 1769-1779
• 13 Ramkumar PN, Navarro SM, Haeberle HS. , et al. Cellular therapy injections in today's orthopedic market: a social media analysis. Cytotherapy 2017; 19 (12) 1392-1399
• 14 Piuzzi NS, Ng M, Chughtai M. , et al. The stem-cell market for the treatment of knee osteoarthritis: a patient perspective. J Knee Surg 2018; 31 (06) 551-556
• 15 Piuzzi NS, Chughtai M, Khlopas A. , et al. Platelet-rich plasma for the treatment of knee osteoarthritis: a review. J Knee Surg 2017; 30 (07) 627-633
• 16 Piuzzi NS, Chahla J, Jiandong H. , et al. Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplasty 2017; 32 (08) 2612-2618
• 17 Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2002; 10 (06) 432-463
• 18 Piuzzi NS, Khlopas A, Sodhi N. , et al. Cellular therapies in orthopedics: where are we?. Surg Technol Int 2017; 31: 359-364
• 19 Chahla J, Piuzzi NS, Mitchell JJ. , et al. Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee. J Bone Jt Surg Am 2016; 98: 1511-1521
• 20 Elmallah RK, Cherian JJ, Jauregui JJ, Pierce TP, Beaver WB, Mont MA. Genetically modified chondrocytes expressing TGF-β1: a revolutionary treatment for articular cartilage damage?. Expert Opin Biol Ther 2015; 15 (03) 455-464
• 21 Ha C-W, Cho JJ, Elmallah RK. , et al. A multicenter, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell-mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev 2015; 26 (02) 125-130
• 22 Lee MC, Ha C-W, Elmallah RK. , et al. A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee. Bone Joint J 2015; 97-B [phone]
• 23 Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthritis Cartilage 2015; 23 (12) 2109-2118
• 24 Cho JJ, Totterman S, Elmallah RK, Kim TW, Lee B, Mont MA. An MRI evaluation of patients who underwent treatment with a cell-mediated gene therapy for degenerative knee arthritis: a phase IIa clinical trial. J Knee Surg 2017; 30 (07) 694-703
• 25 Kohn MD, Sassoon AA, Fernando ND. Classifications in brief: Kellgren–Lawrence classification of osteoarthritis. Clin Orthop Relat Res 2016; 474 (08) 1886-1893
• 26 Peterfy CG, Guermazi A, Zaim S. , et al. Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004; 12 (03) 177-190
• 27 Guermazi A, Kalsi G, Niu J. , et al. Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial. BMC Musculoskelet Disord 2017; 18 (01) 461
• 28 Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International Knee Documentation Committee (IKDC) subjective knee evaluation form, knee injury and osteoarthritis outcome score (KOOS), knee injury and osteoarthritis outcome score physical function short form (KOOS-PS), knee outcome survey activities of daily living scale (KOS-ADL), Lysholm knee scoring scale, Oxford knee score (OKS), Western Ontario and McMaster Universities osteoarthritis index (WOMAC), activity rating scale (ARS), and tegner activity score (TAS). Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11) S208-S228
• 29 Ha C-W, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 2012; 14 (02) 247-256